This piece was first featured on Focal Points and is shared here with the publisher’s consent.
Contributed by Nicolas Hulscher, MPH
A groundbreaking metagenomic research effort under the leadership of Dr. Sabine Hazan meticulously examined stool samples collected from a diverse group of 60 adults. This study included 25 individuals suffering from aggressive forms of cancer, 15 with less severe cancer types, and 20 participants without any cancer diagnosis.
The study encompassed a variety of cancer diagnoses such as breast, lymphoma, colorectal, ovarian, lung, bladder, thyroid, prostate, among others. Through the application of next-generation sequencing technology, Dr. Hazan’s research team sought to evaluate the relative prevalence of crucial bacterial genera in each group.
The study’s most striking revelation was linked to Bifidobacterium, a favorable genus of bacteria known for its roles in bolstering immune function, maintaining the integrity of the intestinal barrier, and enhancing antitumor immune responses.
Aggressive cancer patients had an average Bifidobacterium abundance of just 1.20%, compared with 6.53% in controls (82% less).
They also had 76% less Collinsella, 36% less Faecalibacterium, and 88% more Bacteroides, with all four differences reaching statistical significance.
This pattern is notable because Bifidobacterium, Faecalibacterium, and Collinsella have been associated with healthier immune function and better responses to certain cancer therapies. Some Bacteroides strains, by contrast, have been linked to tumor-promoting activity.
The differences were less pronounced in patients with non-aggressive cancer. Their Bifidobacterium levels were also lower than those of controls, but the result narrowly missed conventional statistical significance.
The findings suggest that more aggressive cancer may be associated with a more severely disrupted gut microbiome. The magnitude of the differences—especially the 82% lower Bifidobacterium abundance—supports larger prospective studies to determine whether these microbial patterns could eventually help identify aggressive cancer or become targets for microbiome-based cancer interventions.
Nicolas Hulscher, MPH
Epidemiologist and Foundation Administrator, McCullough Foundation
www.mcculloughfnd.org
Please consider following both the McCullough Foundation and my personal account on X (formerly Twitter) for further content.
Copyright 2026 Focal Points